NO20014046D0 - Gabapentinderivater for forhindring og behandling av visceral smerte - Google Patents

Gabapentinderivater for forhindring og behandling av visceral smerte

Info

Publication number
NO20014046D0
NO20014046D0 NO20014046A NO20014046A NO20014046D0 NO 20014046 D0 NO20014046 D0 NO 20014046D0 NO 20014046 A NO20014046 A NO 20014046A NO 20014046 A NO20014046 A NO 20014046A NO 20014046 D0 NO20014046 D0 NO 20014046D0
Authority
NO
Norway
Prior art keywords
prevention
treatment
visceral pain
gabapentin derivatives
gabapentin
Prior art date
Application number
NO20014046A
Other languages
English (en)
Norwegian (no)
Other versions
NO20014046L (no
Inventor
Justin Stephen Bryans
Laurent Diop
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of NO20014046L publication Critical patent/NO20014046L/no
Publication of NO20014046D0 publication Critical patent/NO20014046D0/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nutrition Science (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO20014046A 1999-02-23 2001-08-20 Gabapentinderivater for forhindring og behandling av visceral smerte NO20014046D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99400440A EP1031350A1 (en) 1999-02-23 1999-02-23 Use of a gabapentin-analog for the manufacture of a medicament for preventing and treating visceral pain
PCT/EP2000/001103 WO2000050027A1 (en) 1999-02-23 2000-02-03 Gabapentin derivative for preventing and treating visceral pain

Publications (2)

Publication Number Publication Date
NO20014046L NO20014046L (no) 2001-08-20
NO20014046D0 true NO20014046D0 (no) 2001-08-20

Family

ID=8241887

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20014046A NO20014046D0 (no) 1999-02-23 2001-08-20 Gabapentinderivater for forhindring og behandling av visceral smerte

Country Status (14)

Country Link
EP (2) EP1031350A1 (ko)
JP (1) JP2002537332A (ko)
KR (1) KR20010102314A (ko)
CN (1) CN1341018A (ko)
AU (1) AU2909800A (ko)
BR (1) BR0008323A (ko)
CA (1) CA2360528A1 (ko)
CZ (1) CZ20012982A3 (ko)
EA (1) EA200100721A1 (ko)
HK (1) HK1040198A1 (ko)
HU (1) HUP0200344A3 (ko)
IL (1) IL144872A0 (ko)
NO (1) NO20014046D0 (ko)
WO (1) WO2000050027A1 (ko)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002211863A1 (en) 2000-10-06 2002-04-15 Xenoport, Inc. Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration
EP1361847A2 (en) 2000-10-06 2003-11-19 Xenoport, Inc. Bile-acid conjugates for providing sustained systemic concentrations of drugs
EP1226820A1 (en) * 2001-01-26 2002-07-31 Warner-Lambert Company Use of bicyclic amino acids for preventing and treating visceral pain and gastrointestinal disorders
WO2002100347A2 (en) * 2001-06-11 2002-12-19 Xenoport, Inc. Prodrugs of gaba analogs, compositions and uses thereof
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
EP1412324A4 (en) 2001-06-11 2004-09-29 Xenoport Inc AMINO ACID CONJUGATES THAT RESULT IN GABA ANALOGA LASTING SYSTEMIC CONCENTRATIONS
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
KR20030037081A (ko) * 2001-11-02 2003-05-12 한국과학기술연구원 T 타입 칼슘채널을 조절하여 복통을 억제하는 방법
US7045549B2 (en) 2001-11-08 2006-05-16 The Board Of Trustees Of The Leland Stanford Jr. University Treatment of symptoms associated with irritable bowel syndrome
DE10161809A1 (de) * 2001-12-14 2003-06-26 Gruenenthal Gmbh Arzneimittel enthaltend N,N'-disubstituierte Piperazin-Verbindungen
EP1485082A4 (en) 2002-02-19 2009-12-30 Xenoport Inc PROCESS FOR THE SYNTHESIS OF PROMEDICAMENTS FROM 1-ACYL-ALKYL DERIVATIVES AND CORRESPONDING COMPOSITIONS
WO2003080588A1 (en) 2002-03-20 2003-10-02 Xenoport Cyclic 1-(acyloxy)-alkyl prodrugs of gaba analogs, compositions and uses thereof
WO2003099338A2 (en) 2002-05-17 2003-12-04 Xenoport, Inc. Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
JP4399862B2 (ja) * 2002-08-09 2010-01-20 味の素株式会社 腸疾患および内臓痛の治療薬
AU2003297927A1 (en) 2002-12-11 2004-06-30 Xenoport, Inc. Prodrugs of fused gaba analogs, pharmaceutical compositions and uses thereof
ITMI20022658A1 (it) * 2002-12-17 2004-06-18 Nicox Sa Farmaci per il dolore cronico.
MXPA06002731A (es) 2003-09-11 2006-06-05 Xenoport Inc Tratamiento y/o prevencion de incontinencia urinaria utilizando profarmacos de analogos de gaba.
BRPI0414481A (pt) 2003-09-17 2006-11-14 Xenoport Inc métodos de tratamento ou de prevenção da sìndrome das pernas inquietas em um paciente e de melhoria do sono em um paciente com sìndrome das pernas inquietas, e, composição farmacêutica
KR101096480B1 (ko) 2003-10-14 2011-12-20 제노포트 인코포레이티드 감마-아미노부티르산 유사체의 결정질 형태
EP1691811B1 (en) 2003-12-11 2014-07-23 Sunovion Pharmaceuticals Inc. Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
NZ554737A (en) 2004-11-04 2011-04-29 Xenoport Inc Gabapentin prodrug sustained release oral dosage forms
EP3069731A1 (en) 2005-11-14 2016-09-21 Labrys Biologics Inc. Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
WO2008103319A2 (en) 2007-02-16 2008-08-28 Ark Diagnostics, Inc. Compounds and methods for use in detecting gabapentin
WO2009094577A2 (en) 2008-01-25 2009-07-30 Xenoport, Inc. Mesophasic forms of (3s)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use
EP2250148B1 (en) 2008-01-25 2016-08-17 XenoPort, Inc. Crystalline form of calcium-salts of (3s)-aminomethyl-5-methyl-hexanoic acids and methods of use
TWI380812B (zh) 2008-01-25 2013-01-01 Xenoport Inc (3s)-胺甲基-5-甲基己酸前藥之晶形及使用方法
US8293239B2 (en) 2008-03-04 2012-10-23 Pfizer Limited Methods of treating chronic pain
JP2012505238A (ja) 2008-10-08 2012-03-01 カイフィア ファーマシューティカルズ, インコーポレイテッド Gabaコンジュゲートおよびそれらの使用方法
EP2349335B1 (en) 2008-10-24 2013-08-07 ARK Diagnostics, Inc. Levetiracetam immunoassays
BR112012004464B8 (pt) 2009-08-28 2021-05-25 Labrys Biologics Inc uso de um anticorpo antagonista anti-cgrp para preparar uma composição farmacêutica para tratar e/ou prevenir dor visceral e/ou um ou mais sintomas de dor visceral, em que a dor visceral está associada á cistite intersticial (ic), e dita composição farmacêutica
SG194974A1 (en) 2011-05-20 2013-12-30 Alderbio Holdings Llc Use of anti-cgrp or anti-cgrp-r antibodies or antibody fragments to treat or prevent chronic and acute forms of diarrhea
CA3048709A1 (en) 2011-05-20 2012-11-29 Alderbio Holdings Llc Use of anti-cgrp antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers
HUE055505T2 (hu) 2011-05-20 2021-11-29 H Lundbeck As Anti-CGRP készítmények és alkalmazásuk
US9066853B2 (en) 2013-01-15 2015-06-30 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable fiber
EP2945942B1 (en) 2013-01-18 2018-05-09 ARK Diagnostics, Inc. Voriconazole immunoassays
CA2903000C (en) 2013-01-28 2021-10-12 Hector L. Lopez Methods of improving tolerability, pharmacodynamics, and efficacy of .beta.-alanine and use therefor
EP2956444B1 (en) 2013-02-13 2018-05-30 ARK Diagnostics, Inc. Posaconazole immunoassays
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
FI3119431T3 (fi) 2014-03-21 2024-03-20 Teva Pharmaceuticals Int Gmbh Kalsitoniinigeeniin liittyvää peptidiä vastaan suunnattuja antagonisti-vasta-aineita ja menetelmiä niiden käyttämiseksi
CN109952314A (zh) 2016-09-23 2019-06-28 泰瓦制药国际有限公司 治疗难治性偏头痛
KR20210013081A (ko) 2018-05-14 2021-02-03 엑스진 파마슈티컬 인크. 나프록센 및 프레가발린의 1-(아실옥시)-알킬 카르바메이트 약물 복합체의 결정형
CR20210373A (es) 2019-01-08 2021-08-19 H Lundbeck As Tratamiento agudo y tratamiento rápido de la cefalea usando anticuerpos anti-cgrp

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9420784D0 (en) * 1994-10-14 1994-11-30 Glaxo Group Ltd Medicaments
GEP20012413B (en) * 1996-03-14 2001-04-25 Warner Lambert Co Novel Substituted Cyclic Amino Acids as Pharmaceutical Agents
AU8668598A (en) * 1997-08-20 1999-03-08 University Of Oklahoma, The Gaba analogs to prevent and treat gastrointestinal damage

Also Published As

Publication number Publication date
CZ20012982A3 (cs) 2002-05-15
EP1154768A1 (en) 2001-11-21
WO2000050027A1 (en) 2000-08-31
EP1031350A1 (en) 2000-08-30
CN1341018A (zh) 2002-03-20
HUP0200344A3 (en) 2002-11-28
NO20014046L (no) 2001-08-20
AU2909800A (en) 2000-09-14
HUP0200344A2 (hu) 2002-05-29
HK1040198A1 (zh) 2002-05-31
KR20010102314A (ko) 2001-11-15
JP2002537332A (ja) 2002-11-05
BR0008323A (pt) 2002-01-29
CA2360528A1 (en) 2000-08-31
IL144872A0 (en) 2002-06-30
EA200100721A1 (ru) 2002-04-25

Similar Documents

Publication Publication Date Title
NO20014046D0 (no) Gabapentinderivater for forhindring og behandling av visceral smerte
NO20015773D0 (no) Forhindring og behandling av amyloidogen sykdom
NO20022531D0 (no) Vaksine for forebyggelse og behandling av Alzheimer og amyloidrelaterte sykdommer
HUP0201205A3 (en) Prevention and treatment of amyloidogenic disease
NO20002784D0 (no) Forhindring og behandling av amyloidogen sykdom
NO20013380L (no) 2-aminobenzoksazinonderivater for behandling av fedme
NO20013381D0 (no) 2-oksybenzoksazinonderivater for behandling av fedme
NO985484D0 (no) FremgangsmÕte og preparat for behandling og forhindring av hyperurikemi
IL151890A0 (en) Hydroxyphenyl-piperidin 4-ylidene-methyl-benzamide derivatives for the treatment of pain
DE69836209D1 (de) Vorbeugung und behandlunhg des hepatozellulären krebses
IL151765A0 (en) Hydroxyphenyl-piperazinyl-methyl-benzamide derivatives for the treatment of pain
IL151891A0 (en) Quinolinyl-piperidin 4-ylidene-methyl-benzamide derivatives for the treatment of pain
HUP0303306A3 (en) Use of il-18 inhibitors for the treatment and/or prevention of heart disease
NO20020784D0 (no) Medikament for behandling av brudd
EP1173189A4 (en) ASIALOZYTOKINES AND TREATMENT OF LIVER DISEASES
NO20026148D0 (no) Medisiner for forhindring og behandling av neurodegenerative sykdommer
GB9908059D0 (en) Diagnosis and treatment of diseases
NO20022990L (no) Fremgangsmåte og sammensetning for behandling av smerte
IL150208A0 (en) Compound and method for the treatment of pain
NO20013464D0 (no) Anvendelse av 3-isoksazolidinoner og hydroksylaminsyrer for behandling av infeksjoner
NO20014476L (no) Behandling av hiatial hernia
EP1165060A4 (en) PROCESSING OF BILARIAL CALCULATIONS
GB9919565D0 (en) Treatment of disease

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application